Get the Stockscreener App
1.32
0.00%
0.00
After Hours:
1.32
Bioatla Inc stock is traded at $1.32, with a volume of 19,068.
It is up +0.00% in the last 24 hours and down -60.60% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
See More
Previous Close:
$1.32
Open:
$1.25
24h Volume:
19,068
Relative Volume:
0.26
Market Cap:
$2.20M
Revenue:
$2.00M
Net Income/Loss:
$-50.62M
P/E Ratio:
-0.0316
EPS:
-41.8255
Net Cash Flow:
$-37.11M
1W Performance:
-23.92%
1M Performance:
-60.60%
6M Performance:
-84.68%
1Y Performance:
-94.71%
1-Day Range:
$1.16
$1.39
1-Week Range:
$1.07
$1.70
52-Week Range:
$1.07
$71.50
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
1.32 | 5.30M | 2.00M | -50.62M | -37.11M | -41.83 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Initiated | Rodman & Renshaw | Buy |
| Aug-13-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
BioAtla (BCAB) CMO has RSU shares withheld for taxes - Stock Titan
BioAtla (BCAB) CEO still holds 52,035 shares after tax withholding - Stock Titan
BioAtla (BCAB) CFO’s stock move is a tax withholding, not a sale - Stock Titan
BioAtla, Inc. Financial Disclosures & SEC Filings - TradingView
Book value per share of BioAtla, Inc. – OTC:BCAB - TradingView
BioAtla, Inc. Actuals & Estimates (OTC:BCAB) - TradingView
BioAtla, Inc.(NasdaqCM: BCAB) dropped from S&P TMI Index - marketscreener.com
Net current asset value per share of BioAtla, Inc. – OTC:BCAB - TradingView
Price to cash flow ratio of BioAtla, Inc. – OTC:BCAB - TradingView
Enterprise value to EBIT forward of BioAtla, Inc. – OTC:BCAB - TradingView
Enterprise value to EBITDA ratio of BioAtla, Inc. – OTC:BCAB - TradingView
Operating expenses (excl. COGS) of BioAtla, Inc. – OTC:BCAB - TradingView
Operating income of BioAtla, Inc. – OTC:BCAB - TradingView
Diluted earnings per share (diluted EPS) of BioAtla, Inc. – OTC:BCAB - TradingView
After tax other income/expense of BioAtla, Inc. – OTC:BCAB - TradingView
Average basic shares outstanding of BioAtla, Inc. – OTC:BCAB - TradingView
Free cash flow of BioAtla, Inc. – OTC:BCAB - TradingView
Non-controlling/minority interest of BioAtla, Inc. – OTC:BCAB - TradingView
Total revenue of BioAtla, Inc. – OTC:BCAB - TradingView
Cash flow from financing activities of BioAtla, Inc. – OTC:BCAB - TradingView
Gross profit of BioAtla, Inc. – OTC:BCAB - TradingView
Net income before discontinued operations of BioAtla, Inc. – OTC:BCAB - TradingView
Dilution adjustment of BioAtla, Inc. – OTC:BCAB - TradingView
Non-operating income (total) of BioAtla, Inc. – OTC:BCAB - TradingView
Total debt of BioAtla, Inc. – OTC:BCAB - TradingView
BioAtla, Inc. Cash Flow – OTC:BCAB - TradingView
Total equity of BioAtla, Inc. – OTC:BCAB - TradingView
Net debt of BioAtla, Inc. – OTC:BCAB - TradingView
BioAtla, Inc. Statistics – OTC:BCAB - TradingView
BioAtla, Inc. Balance Sheet – OTC:BCAB - TradingView
BioAtla, Inc. Earnings and Revenue – OTC:BCAB - TradingView
BioAtla, Inc. Revenue Breakdown – OTC:BCAB - TradingView
Net income of BioAtla, Inc. – OTC:BCAB - TradingView
BioAtla, Inc. Financial Statements – OTC:BCAB - TradingView
ETFs Investing in BioAtla, Inc. Stocks - TradingView
BioAtla, Inc. Income Statement – OTC:BCAB - TradingView
Free float of BioAtla, Inc. – OTC:BCAB - TradingView
Price to earnings ratio of BioAtla, Inc. – OTC:BCAB - TradingView
Basic earnings per share (basic EPS) of BioAtla, Inc. – OTC:BCAB - TradingView
BCAB Stock Price and Chart — OTC:BCAB - TradingView
BioAtla (BCAB) Holds Steady at $1.74 as Biotech Stock Consolidates Between Key LevelsHedge Fund Favorites - vinanet.vn
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Fails to Halt 44.75% SlideEarnings Outlook Update - vinanet.vn
BioAtla Faces Nasdaq Delisting After Losing Final Appeal - Minichart
BioAtla Faces Nasdaq Delisting, Plans OTC Market Move - TipRanks
BioAtla Received Notice of Delisting - TradingView
BioAtla, Inc.(OTCPK: BCAB) dropped from NASDAQ Composite Index - marketscreener.com
BioAtla (BCAB) Quarterly Figures: The EPS Result Is Above Expectation on the Day; Post-Report: The Share Price Moves Only Slightly in the Latest SessionFull Year Guidance - vinanet.vn
BioAtla (BCAB) Financial Results: The Bottom-Line Figure Outpaces Its Comparison in the Latest Reading; Investor Response: Shares Finish 3.46% Higher in the Latest SessionWeak Earnings Momentum - vinanet.vn
BioAtla Inc. (BCAB) Tumbles 10.4% to $3.09 as Bearish Momentum Tests Key $2.94 SupportTurnaround Stocks - Vinanet
Bioatla Stock Price Forecast. Should You Buy BCAB? - StockInvest.us
BioAtla, Inc. Q2 2026: Revenue $6.5M, EPS $0.27— 10-Q Summary - TradingView
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):